& IMMUNOLOGY

INFECTIOUS DISEASES

INFECTIOUS DISEASES AND IMMUNOLOGY

Infectious Diseases are a significant burden on public health and economic stability of societies all over the world. The threat posed by infectious diseases is deepened by the continued emergence of new, unrecognised pathogens and the re-emergence of old infectious diseases, creating a never-ending cycle. While the emergence of novel treatments will generate new opportunities, important challenges in clinical trials remain – from managing overall costs to maintaining
strict operational oversight. There is also the challenge of patient recruitment – diagnosis of a disease often takes several days, but patients must be enrolled in a study within 24 hours, and some diseases are seasonally active, appearing and disappearing quickly.

THE CHALLENGES

  • Difficulty in finding appropriate patients due to large number of competing trials by many companies
  • Large study size – 31% of Phase III trials need 1000+ patients
  • Lengthy trials result in challenges for patient recruitment and retention
  • KOL / KOI needed to provide expert knowledge for defining actual endpoints – identification of the right lead investigator

OUR SOLUTION

  • Global Scientific Networks – ReSViNET, AfricaNET – enable access to more patients
  • Our multi-country Primary Care Research Network aids in patient recruitment and retention
  • Peer-to-peer Leadership model helps stimulate recruitment and share best practices
  • Our in-house Scientific Officers have extensive knowledge of current infectious disease treatment and trial methodology
2 TRIALS
1158 SITES
125000 PATIENTS

CAPiTA

58 Sites

85000 Patients

Finished

LLI

1100 Sites

40000 Patients

Finished

SCIENTIFIC OFFICERS

A key strength of Julius Clinical is the academic expertise and integrity of our scientific team. Our scientific leaders have broad experience on study committees and are able, through their contacts, to bring together and work effectively with international networks of thought leaders. Our scientific officers related to the therapeutic expertise Infectious diseases and Immunology, are:

PROF. DIEDERICK E. GROBBEE

PROF. DIEDERICK E. GROBBEE

Chief Scientific Officer

Diederick E. (Rick) Grobbee is Chief Scientific Officer at Julius Clinical, and a Professor of Clinical Epidemiology at the University Medical Center (UMC) Utrecht, the Netherlands.

PROF. MARC BONTEN

PROF. MARC BONTEN

Professor of Molecular Epidemiology

Marc Bonten is Professor of Molecular Epidemiology of Infectious Diseases, and head of the department of Medical Microbiology, at the University Medical Center (UMC) Utrecht, the Netherlands.

PROF. LOUIS BONT

PROF. LOUIS BONT

Paediatric Infectious Diseases Specialist

Louis Bont, MD, PhD, is Paediatric Infectious Diseases Specialist and Leader of the RSV Research Group at the University Medical Center Utrecht in Utrecht, The Netherlands.

NETWORKS

Clinical Investigator Networks are a vital element in both academic and clinical research settings. Among peers in the scientific community, investigators communicate and collaborate directly, contributing to the advance of the study imperatives. For this reason, within the clinical research setting, advantages are gained when coordinated research networks are maintained and managed. Networks that are related to the therapeutic expertise Infectious diseases and Immunology, are:

ReSViNET is a global network of experts in the field of Respiratory Syncytial Virus (RSV) infections who are known to be skilled recruiters. Together, they have designed and completed a multitude of RSV trials. ReSViNET consist of 17 board members representing more than 100 trial sites in 13 countries. These sites are academic hospitals with many years of experience in clinical research, enabling fast and high quality recruitment and above average retention rate. RSV is a cyclical illness, and the ReSViNET global network ensures that trials can be conducted throughout the year, following the outbreak of the disease across continents and hemispheres. Because of this, the ReSViNET experts and investigator sites are located around the world, making it a truly international network.

We provide a model infusing scientific leadership, RSV knowledge and trial experience into various levels of complex clinical trials for the benefit of trial outcomes, offering academic leadership and leveraging our RSV knowledge and experience towards the site study team. We deliver our services both for clinical trials in pediatrics as well as trials in older adults.

Please visit the ReSViNET website if you would like to learn more about ReSViNET.

ReSViNET is a global network of experts in the field of Respiratory Syncytial Virus (RSV) infections who are known to be skilled recruiters. Together, they have designed and completed a multitude of RSV trials. ReSViNET consist of 17 board members representing more than 100 trial sites in 13 countries. These sites are academic hospitals with many years of experience in clinical research, enabling fast and high quality recruitment and above average retention rate. RSV is a cyclical illness, and the ReSViNET global network ensures that trials can be conducted throughout the year, following the outbreak of the disease across continents and hemispheres. Because of this, the ReSViNET experts and investigator sites are located around the world, making it a truly international network.

We provide a model infusing scientific leadership, RSV knowledge and trial experience into various levels of complex clinical trials for the benefit of trial outcomes, offering academic leadership and leveraging our RSV knowledge and experience towards the site study team. We deliver our services both for clinical trials in pediatrics as well as trials in older adults.

Please visit the ReSViNET website if you would like to learn more about ReSViNET.